Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

@article{HuLowe2008NonclinicalAA,
  title={Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.},
  author={Dana D. Hu-Lowe and Helen Y. Zou and Maren L. Grazzini and Max Hallin and Grant Raymond Wickman and Karin Kristina Amundson and Jeffrey H. Chen and David A Rewolinski and Shinji Yamazaki and Ellen Y. Wu and Michele A. McTigue and Brion William Murray and Robert Steven Kania and Patrick O'connor and David R. Shalinsky and Steve Bender},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 22},
  pages={
          7272-83
        }
}
PURPOSE Axitinib (AG-013736) is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in clinical development for the treatment of solid tumors. We provide a comprehensive description of its in vitro characteristics and activities, in vivo antiangiogenesis, and antitumor efficacy and translational pharmacology data. EXPERIMENTAL DESIGN The potency, kinase selectivity, pharmacologic activity, and antitumor efficacy of axitinib… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 245 CITATIONS, ESTIMATED 53% COVERAGE

Axitinib: A Review in Advanced Renal Cell Carcinoma

VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Vascular-targeted agents for the treatment of angiosarcoma

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Axitinib for the Management of Metastatic Renal Cell Carcinoma

VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 21 Highly Influenced Citations

  • Averaged 19 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  • The New England journal of medicine
  • 2007
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Axitinib ( AG - 013736 ) is an active treatment for all histological subtypes of advanced thyroid cancer : results from a phase II study

Cohen EEW, LS Rosen, EE Vokes
  • JClin Oncol
  • 2008

A phase II study of the c - Met RTK inhibitor XL 880 in patients ( pts ) with papillary renal - cell carcinoma ( PRC ) [ abstract ]

SteinM Ross RW, SarantopoulosJ
  • JClin Oncol
  • 2007

Efficacy and safety of axitinib ( AG - 013736 ; AG ) in patients ( pts ) with ad - vancednon - small cell lung cancer ( NSCLC ) : a phase II trial [ abstract ]

LarsonT SchillerJH, SI Ou
  • JClin Oncol
  • 2007